HSP90AA1 and colorectal carcinoma: Dual-target inhibition may represent a promising treatment strategy for CRC patient subgroups with Hsp90α/β > 40%/BRAF V600E mutations and Hsp90α/β > 40%/Her2neu Score 3 tumors, which both contribute to particularly poor survival.